Edition:
United States

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

8.42USD
18 Aug 2017
Change (% chg)

$0.44 (+5.51%)
Prev Close
$7.98
Open
$7.89
Day's High
$8.43
Day's Low
$7.70
Volume
737,003
Avg. Vol
551,335
52-wk High
$9.51
52-wk Low
$2.02

IMMU.OQ

Chart for IMMU.OQ

About

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $888.01
Shares Outstanding(Mil.): 111.28
Dividend: --
Yield (%): --

Financials

  IMMU.OQ Industry Sector
P/E (TTM): -- 79.67 32.70
EPS (TTM): -1.44 -- --
ROI: -367.82 2.87 14.88
ROE: -- 5.20 16.12

BRIEF-Immunomedics reports Q4 loss per share $0.48

* Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline

Aug 16 2017

BRIEF-Immunomedics files for offering of 34.8 mln shares of common stock by selling stockholders

* Immunomedics files for offering of 34.8 million shares of common stock by selling stockholders - sec filing

Jul 31 2017

BRIEF-Immunomedics files for 34.8 mln shares of co's common stock

* Files for 34.8 million shares of co's common stock by the selling stockholders - sec filing

Jul 31 2017

BRIEF-Seattle Genetics reports 8.2 percent stake in Immunomedics as of June 29, 2017

* Seattle genetics inc reports a 8.2 percent stake in immunomedics inc as of June 29, 2017 - sec filing

Jul 07 2017

BRIEF-Immunomedics Q3 loss per share $0.55

* Immunomedics announces third quarter fiscal 2017 results and clinical program developments

May 10 2017

BRIEF-Immunomedics announces private placement offering

* Immunomedics delivers business updates, announces private placement offering and outlines strategic steps to drive stockholder value

May 05 2017

BRIEF-Seattle Genetics terminates license agreement with Immunomedics

* Seattle Genetics terminates license agreement with Immunomedics for sacituzumab govitecan (immu-132)

May 05 2017

BRIEF-Seattle Genetics says court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics

* Seattle Genetics- On March 9,court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics

Mar 10 2017

BRIEF-VenBio issues statement to Immunomedics stockholders

* Venbio select advisor llc says issued statement to immunomedics stockholders

Mar 02 2017

BRIEF-Immunomedics outlines revised settlement offer rejected by venBio

* Immunomedics outlines revised settlement offer rejected by venBio; announces actions that are in the best interests of all stockholders

Mar 02 2017

Competitors

Earnings vs. Estimates